Percutaneous treatment of diseased saphenous vein grafts: Current state-of-the-art and future directions

Minerva Cardioangiologica

Volumn 55, Issue 5, 2007, Pages 637-646

  Vermeersch, P ^a   Agostoni, P ^a  

^a MIDDELHEIM HOSPITAL   (Belgium)

Author keywords

Angioplasty, transluminal, percutaneous coronary; Organ graft; Saphenous vein

Indexed keywords

EVEROLIMUS; FIBRINOGEN RECEPTOR ANTAGONIST; IMMUNOSUPPRESSIVE AGENT; PACLITAXEL; RAPAMYCIN; TACROLIMUS; UNCLASSIFIED DRUG; ZOTAROLIMUS;

ANGIOPLASTY; CLINICAL TRIAL; CORONARY STENT; DRUG EFFECT; FOLLOW UP; HUMAN; PERCUTANEOUS CORONARY INTERVENTION; REVIEW; SAPHENOUS VEIN GRAFT; TREATMENT OUTCOME; VEIN GRAFT DISEASE;

ANGIOPLASTY, TRANSLUMINAL, PERCUTANEOUS CORONARY; CORONARY ARTERY DISEASE; CORONARY RESTENOSIS; DRUG-ELUTING STENTS; EVIDENCE-BASED MEDICINE; GRAFT OCCLUSION, VASCULAR; HUMANS; SAPHENOUS VEIN; TREATMENT OUTCOME;

EID: 36749050323     PISSN: 00264725     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Review

References (50)

1. Fitzgibbon G, Kafka H, Leach A, Keon WJ, Hooper GD, Burton JR. Coronary bypass graft fate and patient outcome: angiographic follow-up of 5065grafts related to survival and reoperation in 1 388 patients during 25 years. J Am Coll Cardiol 1996;28:616-26.
2. Alexander JH, Hafley G, Harrington RA, Peterson ED, Ferguson TB, Lorenz TJ et al. Efficacy and safety of edifoligide, an E2F transcription factor decoy, for prevention of vein graft failure following coronary artery bypass graft surgery. PREVENT IV: a randomized controlled trial. JAMA 2005;294:2446-54.
3. Abbate A, Biondi-Zoccai GG, Agostoni P, Lipinski MJ, Vetrovec GW. Recurrent angina after coronary revascularization: a clinical challenge. Eur Heart J 2007;28:1057-65.
4. Weintraub WS, Jones EL, Morris DC, King SB 3rd, Guyton RA, Craver JM. Outcome of reoperative coronary bypass surgery versus coronary angioplasty after previous bypass surgery. Circulation 1997;95:868-77.
5. Salomon N, Page U, Bigelow J, Krause AH, Okies JE, Metzdorff MT. Reoperative coronary surgery: comparative analysis of 6591 patients undergoing primary bypass and 508 patients undergoing reoperative coronary artery bypass. J Thorac Cardiovasc Surg 1990;100:250-9.
6. Baim D. Percutaneous treatment of saphenous vein graft disease the ongoing challenge. J Am Coll Cardiol 2003;42:1370-2.
7. De Feyter P, Van Suylen R, De Jaegere P, Topol EJ, Serruys PW. Balloon angioplasty for the treatment of lesions in saphenous vein bypass grafts. J Am Coll Cardiol 1993;21:1539-49.
8. Serruys PW, de Jaegere P, Kiemeneij F, Macaya C, Rutsch W, Heyndrickx et al. A comparison of balloon-expandable-stent implantation with balloon angioplasty in patients with coronary artery disease. Benestent Study Group. N Engl J Med 1994;331:489-95.
9. Fischman DL, Leon MB, Baim DS, Schatz RA, Savage MP, Penn I et al. A randomized comparison of coronary-stent placement and balloon angioplasty in the treatment of coronary artery disease. Stent Restenosis Study Investigators. N Engl J Med 1994;331:496-501.
10. Wong SC, Baim DS, Schatz RA, Teirstein PS, King SB, Curry RC et al. Immediate results and late outcomes after stent implantation in saphenous vein graft lesions: the multicenter U.S. Palmaz-Schatz stent experience. The Palmaz-Schatz Stent Study Group. J Am Coll Cardiol 1995;26:704-12.
11. Savage M, Douglas J, Fischman D, Pepine CJ, King SB, Werner JA et al. Stent placement compared with balloon angioplasty for obstructed coronary bypass grafts. N Engl J Med 1997;337:740-7.
12. Hanekamp C, Koolen J, Den Heijer P, Schalij MJ, Piek JJ, Bär FW et al. Randomized study to compare balloon angioplasty and elective stent implantation in venous bypass grafts: the VENESTENT study. Cathet Cardiovasc Interv 2003;60:452-7.
13. Biondi-Zoccai GG, Agostoni P, Abbate A. Parallel hierarchy of scientific studies in cardiovascular medicine. Ital Heart J 2003;4:819-20.
14. Silber S, Albertsson P, Aviles FF, Camici PJ, Colombo A, Hamm C et al. Guidelines for percutaneous coronary interventions: the task force for percutaneous coronary interventions of the European society of cardiology. Eur Heart J 2005;26:804-47.
15. Webb J, Carere R, Virmani R, Baim D, Teirstein PS, Whitlow P et al. Retrieval and analysis of particulate debris following saphenous vein graft intervention. J Am Coll Cardiol 1999;34:461-7.
16. Bryan AJ, Angelini GD. The biology of saphenous vein graft occlusion: etiology and strategies for prevention. Curr Opin Cardiol 1994;9:641-9.
17. Depre C, Havaux X, Wijns W. Pathology of restenosis in saphenous bypass grafts after long term implantation. Am J Clin Pathol 1998;110:378-84.
18. Van Beusekom H, Van Der Giessen W, Van Suylen R, Bos E, Bosman FT, Serruys WP. Histology after stenting of human saphenous vein bypass grafts: observations from surgically excised grafts 3 to 320 days after stent implantation. J Am Coll Cardiol 1993;21:45-54.
19. Farb A, Sangiorgi G, Carter A, Walley VM, Edwards WD, Schwartz RS et al. Pathology of acute and chronic coronary stenting in humans. Circulation 1999;99:44-52.
20. Baldus S, Köster R, Elsner M, Walter DH, Arnold R, Auch-Schwelch W et al. Treatment of aortocoronary vein graft lesions with membrane-covered stents: A multicenter surveillance trial. Circulation 2000;102:2024-7.
21. Schächinger V, Hamm CW, Münzel T, Haude M, Baldus S, Grube E et al. A randomized trial of polytetrafluoroethylene-membrane-covered stents compared with conventional stents in aortocoronary saphenous vein grafts. J Am Coll Cardiol 2003;42:1360-9.
22. Stankovic G, Colombo A, Presbitero P, van den Branden F, Inglese L, Cernigliaro C et al. Randomized evaluation of polytetrafluoroethylene- covered stent in saphenous vein grafts: the Randomized Evaluation of polytetrafluoroethylene COVERed stent in Saphenous vein grafts (RECOVERS) Trial. Circulation 2003;108:37-42.
23. Turco MA, Buchbinder M, Popma JJ, Weissman NJ, Mann T, Doucet S et al. Pivotal, randomized U.S. study of the Symbiot covered stent system in patients with saphenous vein graft disease: Eight-month angiographic and clinical results from the Symbiot III trial. Catheter Cardiovasc Interv 2006;68:379-88.
24. Stone G, Goldberg S, Mehran R. A prospective, randomized U.S. trial of the PTFE-covered JOSTENT for the treatment of diseased saphenous vein grafts: the BARRICADE trial (abstr.). J Am Coll Cardiol 2005;45(suppl A):27A.
25. Baim DS, Wahr D, George B, Leon MB, Greenberg J, Cutlip L et al. Randomized trial of a distal embolic protection device during percutaneous intervention of saphenous vein aorto-coronary bypass grafts. Circulation 2002;105:1285-90.
26. Wu CJ, Yang CH, Fang CY, Chang HW, Chen SM, Hung WC et al. Six-month angiographic results of primary angioplasty with adjunctive PercuSurge GuardWire device support: evaluation of the restenotic rate of the target lesion and the fate of the distal balloon occlusion site. Catheter Cardiovasc Interv 2005;64:35-42.
27. Agostoni P, Vermeersch P, Vydt T, Debrauwere J, van den Heuvel P, Convens C et al. Acute and mid-term local vascular effects of compliant balloon inflation (GuardWire system) on saphenous vein bypass grafts: an angiographic analysis. Int J Cardiol 2007;120:227-31.
28. Stone GW, Rogers C, Hermiller J, Feldman R, Hall P, Haber R et al. Randomized comparison of distal protection with a filter-based catheter and a balloon occlusion and aspiration system during percutaneous intervention of diseased saphenous vein aorto-coronary bypass grafts. Circulation 2003;108:548-53.
29. Rogers CB. A prospective randomized comparison of proximal and distal protection in patients with diseased saphenous vein grafts. PROXIMAL trial. Available at http://www.tctmd.com/csportal/appmanager/tctmd/main?_nfpb= true&_pageLabel=TCTMDContent&hdCon=1332055. Last accessed: 3 March 2007.
30. Roffi M, Mukherjee D, Chew DP, Bhatt DL, Cho L, Robbins MA et al. Lack of benefit from intravenous platelet glycoprotein IIb/IIIa receptor inhibition as adjunctive treatment for percutaneous interventions of aortocoronary bypass grafts: a pooled analysis of five randomized clinical trials. Circulation 2002;106:3063-7.
31. Moses J, Leon M, Popma J, Fitzgerald PJ, Holmes DR, O'Shaugnessy C et al., SIRIUS Investigators. Sirolimus-eluting stents versus standard stents in patients with stenosis in a native coronary artery. N Eng J Med 2003;349:1315-23.
32. Stone GW, Ellis SG, Cox DA, Hermiller J, O'Shaugnessy C, Mann JT et al., TAXUS-IV Investigators. A polymer-based, paclitaxel-eluting stent in patients with coronary artery disease. N Engl J Med 2004;350:221-31.
33. Fajadet J, Wijns W, Laarman GJ, Kuck KH, Ormiston J, Munzel T et al.; ENDEAVOR II Investigators. Randomized, double-blind, multicenter study of the Endeavor zotarolimus-eluting phosphorylcholine-encapsulated stent for treatment of native coronary artery lesions: clinical and angiographic results of the ENDEAVOR II trial. Circulation 2006;114:798-806.
34. Ge L, Iakovou I, Sangiorgi G, Chieffo A, Melzi G, Cosgrave J et al. Treatment of saphenous vein graft lesions with drug eluting stents. J Am Coll Cardiol 2005;45:989-94.
35. Chu WW, Rha SW, Kuchulakanti PK, Cheneau E, Torguson R, Pinnow E et al. Efficacy of sirolimus-eluting stents compared with bare metal stents for saphenous vein graft intervention. Am J Cardiol 2006;97:34-7.
36. Hoye A, Lemos PA, Arampatzis CA, Saia F, Tanabe K, Degertekin M et al. Effectiveness of the sirolimus-eluting stent in the treatment of saphenous vein graft disease. J Invasive Cardiol 2004;16:230-3.
37. Tsuchida K, Ong AT, Aoki J, van Mieghem CA, Rodriguez-Granillo GA, Valgimigli M et al. Immediate and one-year outcome of percutaneous intervention of saphenous vein graft disease with paclitaxel-eluting stents. Am J Cardiol 2005;96:395-8.
38. Price M, Sawhney N, Kao JA,.Madrid A, Schatz RA, Teirstein PS. Clinical outcomes after sirolimus-eluting stent implantation for de novo saphenous vein graft lesions. Catheter Cardiovasc Interv 2005;65:208-11.
39. Brunner-La Rocca HP, Kaiser C, Pfisterer M; BASKET Investigators. Targeted stent use in clinical practice based on evidence from the Basel Stent Cost Effectiveness Trial (BASKET). Eur Heart J 2007;28:719-25.
40. Agostoni P, Vermeersch P, Verheye S, Van den Heuvel P, Convens C, Van den Branden F et al. Targeted stent use in clinical practice based on evidence from the Basel Stent Cost Effectiveness Trial (BASKET). Eur Heart J 2007 Jul 2; E-pub ahead of print.
41. Zahn R, Hamm C, Schneider S, Zeymer U, Nienaber CA, Richardt G et al. Incidence and predictors of target vessel revascularization and clinical event rates of the sirolimus-eluting coronary stent (results from the prospective multicenter german cypher stent registry). Am J Cardiol 2005;95:1302-8.
42. Vermeersch P, Agostoni P, Verheye S, van den Heuvel P, Convens C, Braining N et al. Randomized double-blind comparison of sirolimus-eluting stent versus bare metal stent implantation in diseased saphenous vein grafts: 6-month angiographic, intravascular ultrasound and clinical follow up of the RRISC trial. J Am Coll Cardiol 2006;48:2423-31.
43. Agostoni P, Vermeersch P, Semeraro O, Verheye S, van Langenhove G, van den Heuvel P et al. Intravascular ultrasound assessment of sirolimus-eluting stent versus bare metal stent implantation in diseased saphenous vein grafts (from the RRISC [Reduction of Restenosis In Saphenous vein grafts with Cypher sirolimus-eluting stent] trial). Am J Cardiol 2007;100:52-8.
44. Iakovou I, Dangas G, Mintz GS, Mehran R, Kobayashi Y, Aymong E et al. Relation of final lumen dimensions in saphenous vein grafts after stent implantation to outcome. Am J Cardiol 2004;93:963-8.
45. Ellis SG, Brener SJ, DeLuca S, Tuzcu EM, Raymond RE, Whitlow PL et al. Late myocardial ischemic events after saphenous vein graft intervention - importance of initially "nonsignificant" vein graft lesions. Am J Cardiol 1997;79:1460-4.
46. Stone GW, Moses JW, Ellis SG, Schofer J, Dawkins KD, Morice MC et al. Safety and efficacy of sirolimus- and paclitaxel-eluting coronary stents. N Engl J Med 2007;356:998-1008.
47. Daemen J, Wenaweser P, Tsuchida K. Early and late coronary stent thrombosis of sirolimus-eluting and paclitaxel-eluting stents in routine clinical practice: data from a large two-institutional cohort study. Lancet 2007;369:667-78.
48. Bavry AA, Kumbhani DJ, Helton TJ, Borek PP, Mood GR, Bhatt DL. Late thrombosis of drug-eluting stents: a meta-analysis of randomized clinical trials. Am J Med 2006;119:1056-61.
49. Vermeersch P, Agostoni P, Verheye S, van den Heuvel P, Convens C, van den Branden F et al. Increased late mortality after sirolimus-eluting stents versus bare metal stents in diseased saphenous vein grafts: results from the randomized DELAYED RRISC trial. J Am Coll Cardiol 2007;50:261-7.
50. Mauri L, Hsieh WH, Massaro JM, Ho KK. D'Agostino R, Cutlip DE. Stent thrombosis in randomized clinical trials of drug-eluting stents. N Engl J Med 2007;356:1020-9.